AR007058A1 - Uso de interferon en medicamentos y composiciones para contacto oromucosal - Google Patents

Uso de interferon en medicamentos y composiciones para contacto oromucosal

Info

Publication number
AR007058A1
AR007058A1 ARP970101924A ARP970101924A AR007058A1 AR 007058 A1 AR007058 A1 AR 007058A1 AR P970101924 A ARP970101924 A AR P970101924A AR P970101924 A ARP970101924 A AR P970101924A AR 007058 A1 AR007058 A1 AR 007058A1
Authority
AR
Argentina
Prior art keywords
interferon
compositions
medicines
amount
oromucosal contact
Prior art date
Application number
ARP970101924A
Other languages
English (en)
Spanish (es)
Original Assignee
Pharma Pacific Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Pacific Pty Ltd filed Critical Pharma Pacific Pty Ltd
Publication of AR007058A1 publication Critical patent/AR007058A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
ARP970101924A 1996-05-09 1997-05-08 Uso de interferon en medicamentos y composiciones para contacto oromucosal AR007058A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPN9765A AUPN976596A0 (en) 1996-05-09 1996-05-09 Stimulation of host defence mechanisms

Publications (1)

Publication Number Publication Date
AR007058A1 true AR007058A1 (es) 1999-10-13

Family

ID=3794078

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP970101924A AR007058A1 (es) 1996-05-09 1997-05-08 Uso de interferon en medicamentos y composiciones para contacto oromucosal
ARP970101925A AR007059A1 (es) 1996-05-09 1997-05-08 Uso de interferon en la preparacion de medicamentos y composiciones via oromucosal o por contacto

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP970101925A AR007059A1 (es) 1996-05-09 1997-05-08 Uso de interferon en la preparacion de medicamentos y composiciones via oromucosal o por contacto

Country Status (17)

Country Link
EP (2) EP0898478B1 (enExample)
JP (2) JP3806446B2 (enExample)
KR (2) KR100399501B1 (enExample)
CN (1) CN1154508C (enExample)
AR (2) AR007058A1 (enExample)
AT (2) ATE316791T1 (enExample)
AU (3) AUPN976596A0 (enExample)
BR (2) BR9709066A (enExample)
CA (2) CA2253908A1 (enExample)
DE (2) DE69735204T2 (enExample)
ES (2) ES2260794T3 (enExample)
ID (2) ID16886A (enExample)
IL (2) IL126972A0 (enExample)
NZ (2) NZ332690A (enExample)
TW (1) TW528599B (enExample)
WO (2) WO1997041886A1 (enExample)
ZA (1) ZA973988B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6299871B1 (en) * 1998-07-24 2001-10-09 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Orally-administrable therapeutic and/or prophylactic agent for HTLV-1-related diseases
EP1180037A2 (en) * 1999-05-26 2002-02-20 The Brigham and Women's Hospital Therapeutic uses of agents that modulate the activity of alpha-smooth muscle actin
US6710025B1 (en) 1999-05-26 2004-03-23 The Brigham And Women's Hospital, Inc. Treatment of damaged tissue using agents that modulate the activity of alpha-smooth muscle actin
US20040258663A1 (en) * 2003-05-08 2004-12-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of interferon alpha
ES2294589T3 (es) 2004-04-29 2008-04-01 F. Hoffmann-La Roche Ag Variacion de la secuencia nucleosida de ns5a como marcador.
DE102007014752A1 (de) 2007-03-28 2008-10-02 Dusek, Niels, Dr. Verwendung von humanidentischem oder humanaequivalentem rekombinantem Interleukin-2 (heqlL-2) als Therapeutikum in der Human- und Veterinärmedizin

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1982000588A1 (en) * 1980-08-22 1982-03-04 Illinois Univ Delivery of biologically active components of heterologous species interferon isolates
US5286748A (en) * 1981-01-05 1994-02-15 Eby Iii George A General method of shortening the duration of common colds by application of medicaments to tissues of oral cavity
US4820515A (en) * 1982-12-13 1989-04-11 Texas A&M University System Method of using interferon in low dosage to regulate appetite and efficiency of food utilization
US4605555A (en) * 1984-09-20 1986-08-12 Sun Star Kabushiki Kaisha Composition and method for treating keratosic disorder of skin and mucosa
IL76591A0 (en) * 1984-10-05 1986-02-28 Bioferon Biochem Substanz Pharmaceutical compositions containing ifn-ypsilon and processes for the preparation thereof
ZA878295B (en) * 1986-11-06 1988-05-03 Amarillo Cell Culture Co. Inc. Treatment of immuno-resistant disease
JP2704546B2 (ja) * 1989-04-04 1998-01-26 光利 太良 Ａｔｌｌ治療用吸入剤
US5372808A (en) * 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US5215741A (en) * 1990-10-30 1993-06-01 Amarillo Cell Culture Company, Incorporated Method for prevention of parasite infections
JPH06503570A (ja) * 1990-12-14 1994-04-21 シェリング・コーポレーション 肺の悪性腫瘍類を治療するためのアルファーインターフェロンの経口投与
US5780021A (en) * 1993-03-05 1998-07-14 Georgetown University Method for treating type 1 diabetes using α-interferon and/or β-i
IL113280A (en) * 1994-04-12 2004-12-15 Res Dev Foundation A preparation for the treatment of self-immunization diseases with the help of interferon of one type
CN1151841C (zh) * 1996-05-09 2004-06-02 太平洋制药控股公司 干扰素在制备刺激防御机制或免疫反应的药物中的应用

Also Published As

Publication number Publication date
EP0898478A1 (en) 1999-03-03
KR100399501B1 (ko) 2003-12-18
TW528599B (en) 2003-04-21
DE69735201D1 (de) 2006-04-13
NZ332688A (en) 2000-07-28
AU2710997A (en) 1997-11-26
KR100399499B1 (ko) 2003-12-18
CA2253908A1 (en) 1997-11-13
ATE316791T1 (de) 2006-02-15
NZ332690A (en) 2000-07-28
DE69735204D1 (de) 2006-04-13
BR9709066A (pt) 2000-01-04
KR20000010882A (ko) 2000-02-25
AR007059A1 (es) 1999-10-13
BR9709223A (pt) 2000-12-12
EP0956040B1 (en) 2006-02-01
ATE316793T1 (de) 2006-02-15
WO1997041886A1 (en) 1997-11-13
JP2000504027A (ja) 2000-04-04
CN1218409A (zh) 1999-06-02
ID16886A (id) 1997-11-20
DE69735201T2 (de) 2006-09-21
EP0956040A4 (enExample) 1999-11-17
CA2253902A1 (en) 1997-11-13
ID16885A (id) 1997-11-20
AU2399297A (en) 1997-11-26
ES2260790T3 (es) 2006-11-01
ZA973988B (en) 1998-11-09
JP2000504026A (ja) 2000-04-04
JP3806444B2 (ja) 2006-08-09
IL126972A0 (en) 1999-09-22
IL126970A0 (en) 1999-09-22
AU729514B2 (en) 2001-02-01
DE69735204T2 (de) 2006-09-21
CN1154508C (zh) 2004-06-23
WO1997041883A1 (en) 1997-11-13
EP0956040A1 (en) 1999-11-17
KR20000010880A (ko) 2000-02-25
AUPN976596A0 (en) 1996-05-30
AU724190B2 (en) 2000-09-14
EP0898478A4 (en) 1999-05-26
ES2260794T3 (es) 2006-11-01
JP3806446B2 (ja) 2006-08-09
EP0898478B1 (en) 2006-02-01

Similar Documents

Publication Publication Date Title
DK372786D0 (da) Farmaceutiske praeparater af phenindamin
ES2162517T3 (es) Composicion farmaceutica que comprende una combinacion de metformin y fibrato y su uso en la preparacion de medicamentos destinados a reducir la hiperglicemia.
CL2008003938A1 (es) Uso de escitalopram o de una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento del desorden de estres postraumatico (divisional sol. 1799-00).
KR900701252A (ko) 코로 투약하는 벤조디아제핀 최면제
ES2173420T3 (es) Comprimidos que contienen un antibiotico de beta-lactamico y procedimiento para su produccion.
BR9913932A (pt) Uso de análogos de glp-1 no tratamento de derrame
ES2139132T3 (es) Composiciones farmaceuticas activas en la terapia de desordenes del sueño.
ES2157944T3 (es) Nucleos de pastillas de liberacion inmediata de medicamentos insolubles que poseen un recubrimiento de liberacion sostenida.
NO20002851L (no) Blandinger for nasal administrasjon av medikamenter
ES2167061T3 (es) Formas de dosificacion para mejorar la disfuncion erectil en pacientes de sexo masculino.
AR005281A1 (es) Composicion farceutica oral , procedimientos para su manufactura y uso de esa composicion farmaceutica para la preparacion de medicamentos. .
AR012998A1 (es) Uso de un sensibilizador a insulina y de un agente antihiperglucemico para la preparacion de un medicamento y composicion farmaceutica que comprende dichosensibilizador y dicho agente.
AR031682A1 (es) Composiciones farmaceuticas
BR0012082A (pt) Formulação farmacêutica para administração compreendendo morfina e seu uso
AR020803A1 (es) Una composicion que comprende fexofenadina o una sal farmaceuticamente aceptable de la misma y el uso de la misma para la manufactura de unmedicamento
IT8821324A0 (it) Composizioni farmaceutiche ad attivita' analgesica ed antiinfiammatoria per uso orale, dotate di ottima palatabilita' ed esenti da effetti irritanti sulle mucose.
PE68899A1 (es) Composicion que contiene paracetamol
MX9205568A (es) Composicion farmaceutica que contiene cantidades de 5-amino-1beta-d-ribofuranosil-imidazol-4-carboxamida.
AR007058A1 (es) Uso de interferon en medicamentos y composiciones para contacto oromucosal
UY25798A1 (es) Composición farmacéutica de liberación modificada que comprende un sensibilizador de insulina tiazolidinadiónico.
ATE134294T1 (de) Zusammensetzung mit psyllium
UA37278C2 (uk) Протикашльова фармацевтична композиція для перорального введення
PA8449301A1 (es) Composiciones farmaceuticas
AR015956A1 (es) Composiciones de citoquinas oromucosales y usos de las mismas
AR008025A1 (es) Combinación farmacéutica de una tiazolidindiona y un secretagogo de insulina